Home Liver News Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030 – Bulletin Line

Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030 – Bulletin Line

Credits to the Source Link Daniel
non-alcoholic steatohepatitis market insights

Press Release

DelveInsight’s “Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

View report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

DelveInsight launched a new report on Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030.

The key facts of the report:
1. According to DelveInsight, increase in obesity, diabetes population will significantly increase the prevalent cases of NAFLD with the CAGR of 1.02% for the study period i.e. 2016-2027 in the 7MM.
2. Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH.
3. These cases are expected to increase throughout the study period [2016-2027], reaching nearly 47 million cases in 2027.

Key benefits of the report:
1. 11 Years Forecast
2. 7MM Coverage
3. Nonalcoholic Steatohepatitis (NASH) Epidemiology Segmentation
4. Key Cross Competition
5. Highly Analyzed Market
6. Drugs Uptake

Request for sample pages: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.

Key pharma players involved:
1. Genfit
2. Intercept Pharmaceuticals
3. Gilead Sciences
4. Tobira Therapeutics
5. Galmed Pharmaceuticals
6. Bristol-Myers Squibb
7. Cirius Therapeutics
8. Conatus Pharmaceuticals
and many others

Emerging therapies:
1. Obeticholic acid (OCA)
2. Selonsertib
3. Emricasan
4. GR-MD-02
5. IMM-124E
and many others

Download free sample pages: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Table of contents:
1. Key Insights
2. Executive Summary of Nonalcoholic Steatohepatitis (NASH)
3. Competitive Intelligence Analysis for Nonalcoholic Steatohepatitis (NASH)
4. Nonalcoholic Steatohepatitis (NASH): Market Overview at a Glance
5. Nonalcoholic Steatohepatitis (NASH): Disease Background and Overview
6. Patient Journey
7. Nonalcoholic Steatohepatitis (NASH) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Nonalcoholic Steatohepatitis (NASH) Treatment
11. Marketed Products
12. Emerging Therapies
13. Nonalcoholic Steatohepatitis (NASH): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Nonalcoholic Steatohepatitis (NASH)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Related reports:

Nonalcoholic Steatohepatitis (NASH) – Epidemiology Forecast to 2030


Source Link

Related Articles

Leave a Comment

This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: